{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:35:13Z","timestamp":1790868913429,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008758","name":"Council of Science and Technology, Uttar Pradesh","doi-asserted-by":"crossref","award":["3066"],"award-info":[{"award-number":["3066"]}],"id":[{"id":"10.13039\/501100008758","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00203-025-04393-1","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:41:40Z","timestamp":1752770500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unveiling the potential of antimicrobial peptides to combat Mycobacterium tuberculosis"],"prefix":"10.1007","volume":"207","author":[{"given":"Saurabh","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasanpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvnesh Prasad","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdip Singh","family":"Sohal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"4393_CR1","doi-asserted-by":"publisher","unstructured":"Aguilar-P\u00e9rez C et al (2018) Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis. Antimicrob Agents Chemother 62. https:\/\/doi.org\/10.1128\/aac00359-00318","DOI":"10.1128\/aac00359-00318"},{"key":"4393_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antibiotics9010021","volume":"9","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Raqib R, Gu\u00f0mundsson GH, Bergman P, Agerberth B, Rekha RS (2020) Host-directed therapy as a novel treatment strategy to overcome tuberculosis: targeting immune modulation. Antibiotics 9:21","journal-title":"Antibiotics"},{"key":"4393_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","volume":"79","author":"F Ahsan","year":"2002","unstructured":"Ahsan F, Rivas IP, Khan MA, Su\u00e1rez AIT (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers\u2014liposomes and microspheres\u2014on the phagocytosis by macrophages. J Controll Release 79:29\u201340","journal-title":"J Controll Release"},{"key":"4393_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/1567201815666171207163504","volume":"15","author":"M AlMatar","year":"2018","unstructured":"AlMatar M, Makky EA, Var I, Koksal F (2018) The role of nanoparticles in the Inhibition of multidrug-resistant bacteria and biofilms. Curr Drug Deliv 15:470\u2013484","journal-title":"Curr Drug Deliv"},{"key":"4393_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s12602-022-10018-6","volume":"15","author":"A Anbarasu","year":"2023","unstructured":"Anbarasu A (2023) Antimicrobial peptides as immunomodulators and antimycobacterial agents to combat Mycobacterium tuberculosis: a critical review. Probiotics Antimicrob Proteins 15:1539\u20131566","journal-title":"Probiotics Antimicrob Proteins"},{"key":"4393_CR6","doi-asserted-by":"crossref","unstructured":"Avinash Padhi AP, Mitali Sengupta MS, Srabasti Sengupta SS, Roehm K, Avinash Sonawane AS (2014) Antimicrobial peptides and proteins in mycobacterial therapy. Curr Status Fut Prosp","DOI":"10.1016\/j.tube.2014.03.011"},{"key":"4393_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/antibiotics12121732","volume":"12","author":"P Baindara","year":"2023","unstructured":"Baindara P, Mandal SM (2023) Gut-antimicrobial peptides: synergistic co-evolution with antibiotics to combat multi-antibiotic resistance. Antibiotics 12:1732","journal-title":"Antibiotics"},{"key":"4393_CR8","doi-asserted-by":"crossref","unstructured":"Banerjee A et al (2024) Cyclic AMP binding to a universal stress protein in Mycobacterium tuberculosis is essential for viability. J Biol Chem 300","DOI":"10.1016\/j.jbc.2024.107287"},{"key":"4393_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12602-022-09929-1","volume":"14","author":"S Basu","year":"2022","unstructured":"Basu S, Joshi SM, Ramaiah S, Anbarasu A (2022) Designing anti-microbial peptides against major \u00df-lactamase enzymes in clinically important gram-negative bacterial pathogens: an in-silico study. Probiotics Antimicrob Proteins 14:263\u2013276","journal-title":"Probiotics Antimicrob Proteins"},{"key":"4393_CR10","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1016\/j.bbamem.2015.02.012","volume":"1848","author":"ME Bauer","year":"2015","unstructured":"Bauer ME, Shafer WM (2015) On the in vivo significance of bacterial resistance to antimicrobial peptides. Biochim et Biophys Acta (BBA)-Biomemb 1848:3101\u20133111","journal-title":"Biochim et Biophys Acta (BBA)-Biomemb"},{"key":"4393_CR11","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1099\/mic.0.26265-0","volume":"149","author":"G Bell","year":"2003","unstructured":"Bell G, Gouyon P-H (2003) Arming the enemy: the evolution of resistance to self-proteins. Microbiology 149:1367\u20131375","journal-title":"Microbiology"},{"key":"4393_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ijpharm.2014.05.055","volume":"471","author":"S Belotti","year":"2014","unstructured":"Belotti S et al (2014) Spray dried Amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm 471:507\u2013515","journal-title":"Int J Pharm"},{"key":"4393_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"ED Brown","year":"2016","unstructured":"Brown ED, Wright GD (2016) Antibacterial drug discovery in the resistance era. Nature 529:336\u2013343","journal-title":"Nature"},{"key":"4393_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-024-01007-8","volume":"31","author":"M Casanova","year":"2024","unstructured":"Casanova M et al (2024) Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus. J Biomed Sci 31:18","journal-title":"J Biomed Sci"},{"key":"4393_CR15","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.ijid.2022.03.011","volume":"124","author":"J Chakaya","year":"2022","unstructured":"Chakaya J et al (2022) The WHO global tuberculosis 2021 Report\u2013not so good news and turning the tide back to end TB. Int J Infect Dis 124:S26\u2013S29","journal-title":"Int J Infect Dis"},{"key":"4393_CR16","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1073\/pnas.0600997103","volume":"103","author":"JA Champion","year":"2006","unstructured":"Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. Proc Natl Acad Sci 103:4930\u20134934","journal-title":"Proc Natl Acad Sci"},{"key":"4393_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","volume":"25","author":"JA Champion","year":"2008","unstructured":"Champion JA, Walker A, Mitragotri S (2008) Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 25:1815\u20131821","journal-title":"Pharm Res"},{"key":"4393_CR18","doi-asserted-by":"crossref","unstructured":"Chaudhary V, Pal AK, Singla M, Ghosh A (2023) Elucidating the role of c-di-AMP in Mycobacterium smegmatis: phenotypic characterization and functional analysis. Heliyon 9","DOI":"10.1016\/j.heliyon.2023.e15686"},{"key":"4393_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics9010024","volume":"9","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lu TK (2020) Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics 9:24","journal-title":"Antibiotics"},{"key":"4393_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/089426802760292672","volume":"15","author":"NY Chew","year":"2002","unstructured":"Chew NY, Chan H-K (2002) The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 15:325\u2013330","journal-title":"J Aerosol Med"},{"key":"4393_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.peptides.2015.07.021","volume":"71","author":"S Chingat\u00e9","year":"2015","unstructured":"Chingat\u00e9 S, Delgado G, Salazar LM, Soto C-Y (2015) The ATPase activity of the mycobacterial plasma membrane is inhibited by the LL37-analogous peptide LLAP. Peptides 71:222\u2013228","journal-title":"Peptides"},{"key":"4393_CR22","doi-asserted-by":"publisher","first-page":"1403900","DOI":"10.3389\/fphar.2024.1403900","volume":"15","author":"M Chouhan","year":"2024","unstructured":"Chouhan M et al (2024) Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in Mycobacterium tuberculosis: A computational approach. Front Pharmacol 15:1403900","journal-title":"Front Pharmacol"},{"key":"4393_CR23","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1128\/AAC.49.7.2845-2850.2005","volume":"49","author":"CD Ciornei","year":"2005","unstructured":"Ciornei CD, Sigurdard\u00f3ttir T, Schmidtchen A, Bodelsson M (2005) Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and Inhibition by serum of analogs of human Cathelicidin LL-37. Antimicrob Agents Chemother 49:2845\u20132850","journal-title":"Antimicrob Agents Chemother"},{"key":"4393_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ddr.20456","volume":"72","author":"MB Conde","year":"2011","unstructured":"Conde MB, Lapa e Silva JR (2011) New regimens for reducing the duration of treatment of drug-susceptible pulmonary tuberculosis. Drug Dev Res 72:501\u2013508","journal-title":"Drug Dev Res"},{"key":"4393_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pep.2013.02.007","volume":"89","author":"L Corrales-Garcia","year":"2013","unstructured":"Corrales-Garcia L, Ortiz E, Casta\u00f1eda-Delgado J, Rivas-Santiago B, Corzo G (2013) Bacterial expression and antibiotic activities of Recombinant variants of human \u00df-defensins on pathogenic bacteria and M. tuberculosis. Protein Exp Purif 89:33\u201343","journal-title":"Protein Exp Purif"},{"key":"4393_CR26","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.mtla.2019.100494","volume":"8","author":"JAF Corr\u00eaa","year":"2019","unstructured":"Corr\u00eaa JAF, Evangelista AG, de Melo Nazareth T, Luciano FB (2019) Fundamentals on the molecular mechanism of action of antimicrobial peptides. Materialia 8:100494","journal-title":"Materialia"},{"key":"4393_CR27","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1016\/j.febslet.2015.11.002","volume":"589","author":"KJ Cutrona","year":"2015","unstructured":"Cutrona KJ, Kaufman BA, Figueroa DM, Elmore DE (2015) Role of arginine and lysine in the antimicrobial mechanism of histone-derived antimicrobial peptides. FEBS Lett 589:3915\u20133920","journal-title":"FEBS Lett"},{"key":"4393_CR28","doi-asserted-by":"publisher","first-page":"107968","DOI":"10.1016\/j.biotechadv.2022.107968","volume":"59","author":"S Deo","year":"2022","unstructured":"Deo S, Turton KL, Kainth T, Kumar A, Wieden H-J (2022) Strategies for improving antimicrobial peptide production. Biotechnol Adv 59:107968","journal-title":"Biotechnol Adv"},{"key":"4393_CR29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.2174\/138161209788682325","volume":"15","author":"G Diamond","year":"2009","unstructured":"Diamond G, Beckloff N, Weinberg A, Kisich KO (2009) The roles of antimicrobial peptides in innate host defense. Curr Pharm Design 15:2377\u20132392","journal-title":"Curr Pharm Design"},{"key":"4393_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/jpdtsm.jpdtsm_123_23","volume":"3","author":"P Eslami","year":"2024","unstructured":"Eslami P, Khosravi A (2024) Antimicrobial peptides as new-generation antibiotics against Mycobacterium. J Prev Diagn Treat Strategies Med 3:6\u201314","journal-title":"J Prev Diagn Treat Strategies Med"},{"key":"4393_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/ijms17050785","volume":"17","author":"A Falanga","year":"2016","unstructured":"Falanga A et al (2016) Marine antimicrobial peptides: nature provides templates for the design of novel compounds against pathogenic bacteria. Int J Mol Sci 17:785","journal-title":"Int J Mol Sci"},{"key":"4393_CR32","unstructured":"Falzon D et al (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. In: European Respiratory Society"},{"key":"4393_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.peptides.2004.04.003","volume":"25","author":"L Fattorini","year":"2004","unstructured":"Fattorini L et al (2004) In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 25:1075\u20131077","journal-title":"Peptides"},{"key":"4393_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","volume":"11","author":"CD Fjell","year":"2012","unstructured":"Fjell CD, Hiss JA, Hancock RE, Schneider G (2012) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11:37\u201351","journal-title":"Nat Rev Drug Discov"},{"key":"4393_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156802608783955629","volume":"8","author":"M Gaspar","year":"2008","unstructured":"Gaspar M, Cruz A, Fraga A, Castro AG, Cruz M, Pedrosa J (2008) Developments on drug delivery systems for the treatment of mycobacterial infections. Curr Top Med Chem 8:579\u2013591","journal-title":"Curr Top Med Chem"},{"key":"4393_CR36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1164\/rccm.200504-613PP","volume":"172","author":"S Gelperina","year":"2005","unstructured":"Gelperina S, Kisich K, Iseman MD, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487\u20131490","journal-title":"Am J Respir Crit Care Med"},{"key":"4393_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nm0307-290","volume":"13","author":"AM Ginsberg","year":"2007","unstructured":"Ginsberg AM, Spigelman M (2007) Challenges in tuberculosis drug research and development. Nat Med 13:290\u2013294","journal-title":"Nat Med"},{"key":"4393_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1365-2672.2005.02552.x","volume":"98","author":"C Guinane","year":"2005","unstructured":"Guinane C, Cotter P, Hill C, Ross R (2005) Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food. J Appl Microbiol 98:1316\u20131325","journal-title":"J Appl Microbiol"},{"key":"4393_CR39","doi-asserted-by":"crossref","unstructured":"Gupta S, Sharma A, KAUR R, Goel A, Vir Singh S (2023) Phage therapy to combat mycobacterial infections: a therapeutic perspective. Minerva Biotechnol Biomol Res 35","DOI":"10.23736\/S2724-542X.23.03019-5"},{"key":"4393_CR40","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbamem.2016.01.031","volume":"1858","author":"T Gutsmann","year":"2016","unstructured":"Gutsmann T (2016) Interaction between antimicrobial peptides and mycobacteria. Biochim Et Biophys Acta (BBA)-Biomembranes 1858:1034\u20131043","journal-title":"Biochim Et Biophys Acta (BBA)-Biomembranes"},{"key":"4393_CR41","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"RE Hancock","year":"2006","unstructured":"Hancock RE, Sahl H-G (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551\u20131557","journal-title":"Nat Biotechnol"},{"key":"4393_CR42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/bip.22250","volume":"100","author":"EF Haney","year":"2013","unstructured":"Haney EF, Hancock RE (2013) Peptide design for antimicrobial and Immunomodulatory applications. Pept Sci 100:572\u2013583","journal-title":"Pept Sci"},{"key":"4393_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214\u2013221","journal-title":"Nat Rev Drug Discov"},{"key":"4393_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1126\/science.aad4977","volume":"352","author":"CC Hicks","year":"2016","unstructured":"Hicks CC et al (2016) Engage key social concepts for sustainability. Science 352:38\u201340","journal-title":"Science"},{"key":"4393_CR45","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3390\/microorganisms11092225","volume":"11","author":"K Hilpert","year":"2023","unstructured":"Hilpert K, Munshi T, L\u00f3pez-P\u00e9rez PM, Sequeira-Garcia J, Hofmann S, Bull TJ (2023) Discovery of antimicrobial peptides that can accelerate culture diagnostics of slow-growing mycobacteria including Mycobacterium tuberculosis. Microorganisms 11:2225","journal-title":"Microorganisms"},{"key":"4393_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0609-3","volume":"14","author":"I Honeyborne","year":"2016","unstructured":"Honeyborne I et al (2016) Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Med 14:1\u201313","journal-title":"BMC Med"},{"key":"4393_CR47","doi-asserted-by":"publisher","first-page":"582779","DOI":"10.3389\/fmicb.2020.582779","volume":"11","author":"Y Huan","year":"2020","unstructured":"Huan Y, Kong Q, Mou H, Yi H (2020) Antimicrobial peptides: classification, design, application and research progress in multiple fields. Front Microbiol 11:582779","journal-title":"Front Microbiol"},{"key":"4393_CR48","doi-asserted-by":"publisher","first-page":"1194923","DOI":"10.3389\/fimmu.2023.1194923","volume":"14","author":"YM Jacobo-Delgado","year":"2023","unstructured":"Jacobo-Delgado YM, Rodr\u00edguez-Carlos A, Serrano CJ, Rivas-Santiago B (2023) Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible? Front Immunol 14:1194923","journal-title":"Front Immunol"},{"key":"4393_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/092986611794578288","volume":"18","author":"Z Jiang","year":"2011","unstructured":"Jiang Z, Higgins P, Whitehurst M, Kisich JO, Voskuil KI, Hodges MS R (2011) Anti-tuberculosis activity of a-helical antimicrobial peptides: de Novo designed L-and D-enantiomers versus L-and D-LL37. Protein Pept Lett 18:241\u2013252","journal-title":"Protein Pept Lett"},{"key":"4393_CR50","volume-title":"Understanding the mechanisms of drug resistance in enhancing rapid molecular detection of drug resistance in Mycobacterium tuberculosis","author":"R Johnson","year":"2007","unstructured":"Johnson R (2007) Understanding the mechanisms of drug resistance in enhancing rapid molecular detection of drug resistance in Mycobacterium tuberculosis. University of Stellenbosch, Stellenbosch"},{"key":"4393_CR51","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1086\/424463","volume":"190","author":"A Kalita","year":"2004","unstructured":"Kalita A, Verma I, Khuller G (2004) Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 190:1476\u20131480","journal-title":"J Infect Dis"},{"key":"4393_CR52","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1039\/d0mt00040j","volume":"12","author":"B Katarzyna","year":"2020","unstructured":"Katarzyna B, Taylor RM, Szpunar J, Lobinski R, Sunde RA (2020) Identification and determination of selenocysteine, selenosugar, and other selenometabolites in Turkey liver. Metallomics 12:758\u2013766","journal-title":"Metallomics"},{"key":"4393_CR53","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1007\/s00436-002-0769-2","volume":"90","author":"O Kayser","year":"2003","unstructured":"Kayser O, Olbrich C, Croft S, Kiderlen A (2003) Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res 90:S63\u2013S70","journal-title":"Parasitol Res"},{"key":"4393_CR54","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.biomaterials.2013.11.035","volume":"35","author":"JS Khara","year":"2014","unstructured":"Khara JS et al (2014) Anti-mycobacterial activities of synthetic cationic a-helical peptides and their synergism with rifampicin. Biomaterials 35:2032\u20132038","journal-title":"Biomaterials"},{"key":"4393_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.actbio.2015.09.015","volume":"28","author":"JS Khara","year":"2015","unstructured":"Khara JS et al (2015) Designing a-helical peptides with enhanced synergism and selectivity against Mycobacterium smegmatis: discerning the role of hydrophobicity and helicity. Acta Biomater 28:99\u2013108","journal-title":"Acta Biomater"},{"key":"4393_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12951","volume":"301","author":"G Kilin\u00e7","year":"2021","unstructured":"Kilin\u00e7 G, Saris A, Ottenhoff TH, Haks MC (2021) Host-directed therapy to combat mycobacterial infections. Immunol Rev 301:62\u201383","journal-title":"Immunol Rev"},{"key":"4393_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/13543776.2016.1176149","volume":"26","author":"P Kosikowska","year":"2016","unstructured":"Kosikowska P, Lesner A (2016) Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003\u20132015). Expert Opin Ther Pat 26:689\u2013702","journal-title":"Expert Opin Ther Pat"},{"key":"4393_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijpharm.2015.07.001","volume":"491","author":"PCL Kwok","year":"2015","unstructured":"Kwok PCL et al (2015) Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Int J Pharm 491:367\u2013374","journal-title":"Int J Pharm"},{"key":"4393_CR59","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.tube.2014.08.001","volume":"94","author":"Y Lan","year":"2014","unstructured":"Lan Y, Lam JT, Siu GK, Yam WC, Mason AJ, Lam JK (2014) Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis 94:678\u2013689","journal-title":"Tuberculosis"},{"key":"4393_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2017.00073","volume":"11","author":"J Li","year":"2017","unstructured":"Li J, Koh J-J, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW (2017) Membrane active antimicrobial peptides: translating mechanistic insights to design. Front NeuroSci 11:73","journal-title":"Front NeuroSci"},{"key":"4393_CR61","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/pharmaceutics15092278","volume":"15","author":"H Li","year":"2023","unstructured":"Li H, Niu J, Wang X, Niu M, Liao C (2023) The contribution of antimicrobial peptides to immune cell function: a review of recent advances. Pharmaceutics 15:2278","journal-title":"Pharmaceutics"},{"key":"4393_CR62","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu PT et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770\u20131773","journal-title":"Science"},{"key":"4393_CR63","first-page":"25","volume":"18","author":"L London","year":"2016","unstructured":"London L, Cox H, Coomans F (2016) Multidrug-resistant TB: implementing the right to health through the right to enjoy the benefits of scientific progress. Health Hum Rights 18:25","journal-title":"Health Hum Rights"},{"key":"4393_CR64","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1021\/jp067127g","volume":"111","author":"MR Lourenzoni","year":"2007","unstructured":"Lourenzoni MR, Namba AM, Caseli L, Degr\u00e8ve L, Zaniquelli ME (2007) Study of the interaction of human defensins with cell membrane models: relationships between structure and biological activity. J Phys Chem B 111:11318\u201311329","journal-title":"J Phys Chem B"},{"key":"4393_CR65","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/nn2000756","volume":"5","author":"O Lunov","year":"2011","unstructured":"Lunov O et al (2011) Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 5:1657\u20131669","journal-title":"ACS Nano"},{"key":"4393_CR66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/fermentation10110540","volume":"10","author":"X Ma","year":"2024","unstructured":"Ma X et al (2024) A review of antimicrobial peptides: structure, mechanism of action, and molecular optimization strategies. Fermentation 10:540","journal-title":"Fermentation"},{"key":"4393_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","volume":"6","author":"M Mahlapuu","year":"2016","unstructured":"Mahlapuu M, H\u00e5kansson J, Ringstad L, Bj\u00f6rn C (2016) Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol 6:194","journal-title":"Front Cell Infect Microbiol"},{"key":"4393_CR68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cocis.2010.05.016","volume":"15","author":"M Malmsten","year":"2010","unstructured":"Malmsten M, Bysell H, Hansson P (2010) Biomacromolecules in microgels\u2014Opportunities and challenges for drug delivery. Curr Opin Colloid Interface Sci 15:435\u2013444","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"4393_CR69","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/pharmaceutics11090448","volume":"11","author":"\u00c1 Martin-Serrano","year":"2019","unstructured":"Martin-Serrano \u00c1, G\u00f3mez R, Ortega P, de la Mata FJ (2019) Nanosystems as vehicles for the delivery of antimicrobial peptides (AMPs). Pharmaceutics 11:448","journal-title":"Pharmaceutics"},{"key":"4393_CR70","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1172\/JCI31097","volume":"117","author":"AR Martineau","year":"2007","unstructured":"Martineau AR et al (2007) Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Investig 117:1988\u20131994","journal-title":"J Clin Investig"},{"key":"4393_CR71","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.bbamem.2008.09.013","volume":"1788","author":"K Matsuzaki","year":"2009","unstructured":"Matsuzaki K (2009) Control of cell selectivity of antimicrobial peptides. Biochim Et Biophys Acta (BBA)-Biomembranes 1788:1687\u20131692","journal-title":"Biochim Et Biophys Acta (BBA)-Biomembranes"},{"key":"4393_CR72","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1086\/518655","volume":"196","author":"H McIlleron","year":"2007","unstructured":"McIlleron H, Meintjes G, Burman WJ, Maartens G (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196:S63\u2013S75","journal-title":"J Infect Dis"},{"key":"4393_CR73","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2174\/1574893618666230419081901","volume":"18","author":"K Mehta","year":"2023","unstructured":"Mehta K, Vyas P, Mujawar S, Hazam PK, Vyas A (2023) Design and In-silico screening of short antimicrobial peptides (AMPs) as Anti-Tubercular agents targeting INHA. Curr Bioinform 18:715\u2013736","journal-title":"Curr Bioinform"},{"key":"4393_CR74","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1128\/CVI.00178-08","volume":"15","author":"P M\u00e9ndez-Samperio","year":"2008","unstructured":"M\u00e9ndez-Samperio P, Miranda E, Trejo A (2008) Expression and secretion of Cathelicidin LL-37 in human epithelial cells after infection by Mycobacterium bovis Bacillus Calmette-Guerin. Clin Vaccine Immunol 15:1450\u20131455","journal-title":"Clin Vaccine Immunol"},{"key":"4393_CR75","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.bbamem.2015.12.013","volume":"1858","author":"R Mikut","year":"2016","unstructured":"Mikut R, Ruden S, Reischl M, Breitling F, Volkmer R, Hilpert K (2016) Improving short antimicrobial peptides despite elusive rules for activity. Biochim Et Biophys Acta (BBA)-Biomembranes 1858:1024\u20131033","journal-title":"Biochim Et Biophys Acta (BBA)-Biomembranes"},{"key":"4393_CR76","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/antibiotics13090794","volume":"13","author":"KH Min","year":"2024","unstructured":"Min KH, Kim KH, Ki M-R, Pack SP (2024) Antimicrobial peptides and their biomedical applications: A review. Antibiotics 13:794","journal-title":"Antibiotics"},{"key":"4393_CR77","doi-asserted-by":"publisher","first-page":"14499","DOI":"10.1002\/jcb.28711","volume":"120","author":"SK Miryala","year":"2019","unstructured":"Miryala SK, Anbarasu A, Ramaiah S (2019) Impact of bedaquiline and capreomycin on the gene expression patterns of multidrug-resistant Mycobacterium tuberculosis H37Rv strain and Understanding the molecular mechanism of antibiotic resistance. J Cell Biochem 120:14499\u201314509","journal-title":"J Cell Biochem"},{"key":"4393_CR78","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1128\/iai.64.3.926-932.1996","volume":"64","author":"Y Miyakawa","year":"1996","unstructured":"Miyakawa Y et al (1996) In vitro activity of the antimicrobial peptides human and rabbit defensins and Porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 64:926\u2013932","journal-title":"Infect Immun"},{"key":"4393_CR79","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1128\/AAC.02475-12","volume":"57","author":"S Mohanty","year":"2013","unstructured":"Mohanty S et al (2013) Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Chemother 57:3688\u20133698","journal-title":"Antimicrob Agents Chemother"},{"key":"4393_CR80","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1086\/344657","volume":"36","author":"JB Nachega","year":"2003","unstructured":"Nachega JB, Chaisson RE (2003) Tuberculosis drug resistance: a global threat. Clin Infect Dis 36:S24\u2013S30","journal-title":"Clin Infect Dis"},{"key":"4393_CR81","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/0929866530666230315113624","volume":"30","author":"Y Ning","year":"2023","unstructured":"Ning Y, Wang L, Wang M, Meng X, Qiao J (2023) Antimicrobial peptides: A promising strategy for Anti-tuberculosis therapeutics. Protein Pept Lett 30:280\u2013294","journal-title":"Protein Pept Lett"},{"key":"4393_CR82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cis.2017.01.005","volume":"242","author":"R Nordstr\u00f6m","year":"2017","unstructured":"Nordstr\u00f6m R, Malmsten M (2017) Delivery systems for antimicrobial peptides. Adv Colloid Interface Sci 242:17\u201334","journal-title":"Adv Colloid Interface Sci"},{"key":"4393_CR83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cis.2016.11.003","volume":"238","author":"L Nystr\u00f6m","year":"2016","unstructured":"Nystr\u00f6m L, Malmsten M (2016) Surface-bound microgels\u2014From physicochemical properties to biomedical applications. Adv Colloid Interface Sci 238:88\u2013104","journal-title":"Adv Colloid Interface Sci"},{"key":"4393_CR84","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1021\/bi992408i","volume":"39","author":"Z Oren","year":"2000","unstructured":"Oren Z, Shai Y (2000) Cyclization of a cytolytic amphipathic a-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. Biochemistry 39:6103\u20136114","journal-title":"Biochemistry"},{"key":"4393_CR85","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkg477","volume":"52","author":"R Pandey","year":"2003","unstructured":"Pandey R, Sharma A, Zahoor A, Sharma S, Khuller G, Prasad B (2003) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981\u2013986","journal-title":"J Antimicrob Chemother"},{"key":"4393_CR86","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1038\/s41467-024-48588-4","volume":"15","author":"C Peng","year":"2024","unstructured":"Peng C et al (2024) Mycobacterium tuberculosis suppresses host antimicrobial peptides by dehydrogenating L-alanine. Nat Commun 15:4216","journal-title":"Nat Commun"},{"key":"4393_CR87","doi-asserted-by":"publisher","first-page":"1183247","DOI":"10.3389\/fmicb.2023.1183247","volume":"14","author":"G Polin\u00e1rio","year":"2023","unstructured":"Polin\u00e1rio G et al (2023) Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer. Front Microbiol 14:1183247","journal-title":"Front Microbiol"},{"key":"4393_CR88","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1128\/AAC.00428-13","volume":"57","author":"D Pulido","year":"2013","unstructured":"Pulido D, Torrent M, Andreu D, Nogu\u00e9s MV, Boix E (2013) Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7. Antimicrob Agents Chemother 57:3797\u20133805","journal-title":"Antimicrob Agents Chemother"},{"key":"4393_CR89","doi-asserted-by":"crossref","unstructured":"Rajput S, Gupta S, Chaturvedi T (2023) Impact of the COVID-19 pandemic on tuberculosis management in India: a brief overview","DOI":"10.18006\/2023.11(3).534.541"},{"key":"4393_CR90","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1128\/AAC.00175-13","volume":"57","author":"S Ram\u00f3n-Garc\u00eda","year":"2013","unstructured":"Ram\u00f3n-Garc\u00eda S et al (2013) Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 57:2295\u20132303","journal-title":"Antimicrob Agents Chemother"},{"key":"4393_CR91","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1080\/15548627.2015.1075110","volume":"11","author":"RS Rekha","year":"2015","unstructured":"Rekha RS et al (2015) Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy 11:1688\u20131699","journal-title":"Autophagy"},{"key":"4393_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.micres.2016.04.008","volume":"191","author":"AC Rios","year":"2016","unstructured":"Rios AC et al (2016) Alternatives to overcoming bacterial resistances: State-of-the-art. Microbiol Res 191:51\u201380","journal-title":"Microbiol Res"},{"key":"4393_CR93","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2249.2010.04313.x","volume":"164","author":"C Rivas-Santiago","year":"2011","unstructured":"Rivas-Santiago C, Rivas-Santiago B, Le\u00f3n D, Casta\u00f1eda-Delgado J, Hernandez Pando R (2011) Induction of \u00df-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin Experimental Immunol 164:80\u201389","journal-title":"Clin Experimental Immunol"},{"key":"4393_CR94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2012.09.015","volume":"41","author":"B Rivas-Santiago","year":"2013","unstructured":"Rivas-Santiago B, Santiago CER, Casta\u00f1eda-Delgado JE, Le\u00f3n\u2013Contreras JC, Hancock RE, Hernandez-Pando R (2013) Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 41:143\u2013148","journal-title":"Int J Antimicrob Agents"},{"key":"4393_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","volume":"211","author":"JJ Saukkonen","year":"2025","unstructured":"Saukkonen JJ et al (2025) Updates on the treatment of Drug-Susceptible and Drug-Resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 211:15\u201333","journal-title":"Am J Respir Crit Care Med"},{"key":"4393_CR96","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/bip.10260","volume":"66","author":"Y Shai","year":"2002","unstructured":"Shai Y (2002) Mode of action of membrane active antimicrobial peptides. Pept Science: Original Res Biomolecules 66:236\u2013248","journal-title":"Pept Science: Original Res Biomolecules"},{"key":"4393_CR97","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1074\/jbc.271.13.7305","volume":"271","author":"Y Shai","year":"1996","unstructured":"Shai Y, Oren Z (1996) Diastereomers of cytolysins, a novel class of potent antibacterial peptides. J Biol Chem 271:7305\u20137308","journal-title":"J Biol Chem"},{"key":"4393_CR98","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1034\/j.1399-3003.2000.16a20.x","volume":"16","author":"S Sharma","year":"2000","unstructured":"Sharma S, Verma I, Khuller G (2000) Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 16:112\u2013117","journal-title":"Eur Respir J"},{"key":"4393_CR99","doi-asserted-by":"publisher","first-page":"121097","DOI":"10.1016\/j.ijpharm.2021.121097","volume":"608","author":"A Sharma","year":"2021","unstructured":"Sharma A et al (2021) Antimicrobial activity of synthetic antimicrobial peptides loaded in poly-?-caprolactone nanoparticles against mycobacteria and their functional synergy with rifampicin. Int J Pharm 608:121097","journal-title":"Int J Pharm"},{"key":"4393_CR100","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4046\/trd.2015.78.3.161","volume":"78","author":"H-J Shin","year":"2015","unstructured":"Shin H-J, Kwon Y-S (2015) Treatment of drug susceptible pulmonary tuberculosis. Tuberc Respir Dis 78:161","journal-title":"Tuberc Respir Dis"},{"key":"4393_CR101","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10989-018-9677-x","volume":"25","author":"G Shu","year":"2019","unstructured":"Shu G, Chen Y, Liu T, Ren S, Kong Y (2019) Antimicrobial peptide cathelicidin-BF inhibits platelet aggregation by blocking protease-activated receptor 4. Int J Pept Res Ther 25:349\u2013358","journal-title":"Int J Pept Res Ther"},{"key":"4393_CR102","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biotechadv.2016.05.007","volume":"34","author":"JP Silva","year":"2016","unstructured":"Silva JP, Appelberg R, Gama FM (2016) Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv 34:924\u2013940","journal-title":"Biotechnol Adv"},{"key":"4393_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/0929866525666181026160852","volume":"26","author":"R Sinha","year":"2019","unstructured":"Sinha R, Shukla P (2019) Antimicrobial peptides: recent insights on biotechnological interventions and future perspectives. Protein Pept Lett 26:79\u201387","journal-title":"Protein Pept Lett"},{"key":"4393_CR104","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1462-5822.2011.01644.x","volume":"13","author":"A Sonawane","year":"2011","unstructured":"Sonawane A et al (2011) Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol 13:1601\u20131617","journal-title":"Cell Microbiol"},{"key":"4393_CR105","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1189\/jlb.0407216","volume":"82","author":"FB Sow","year":"2007","unstructured":"Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP (2007) Expression and localization of Hepcidin in macrophages: a role in host defense against tuberculosis. J Leucocyte Biology 82:934\u2013945","journal-title":"J Leucocyte Biology"},{"key":"4393_CR106","doi-asserted-by":"publisher","first-page":"1582863","DOI":"10.3389\/fmicb.2025.1582863","volume":"16","author":"Z Su","year":"2025","unstructured":"Su Z, Yu H, Lv T, Chen Q, Luo H, Zhang H (2025) Progress in the classification, optimization, activity, and application of antimicrobial peptides. Front Microbiol 16:1582863","journal-title":"Front Microbiol"},{"key":"4393_CR107","doi-asserted-by":"publisher","first-page":"e151228","DOI":"10.3201\/eid2203.151228","volume":"22","author":"T Sullivan","year":"2016","unstructured":"Sullivan T, Amor YB (2016) Global introduction of new multidrug-resistant tuberculosis drugs\u2014Balancing regulation with urgent patient needs. Emerg Infect Dis 22:e151228","journal-title":"Emerg Infect Dis"},{"key":"4393_CR108","doi-asserted-by":"publisher","first-page":"10686","DOI":"10.1002\/anie.201103589","volume":"50","author":"M Torrent","year":"2011","unstructured":"Torrent M, Valle J, Nogu\u00e9s MV, Boix E, Andreu D (2011) The generation of antimicrobial peptide activity: a trade-off between charge and aggregation? Angewandte Chemie-International Ed 50:10686","journal-title":"Angewandte Chemie-International Ed"},{"key":"4393_CR109","doi-asserted-by":"publisher","first-page":"fty005","DOI":"10.1093\/femspd\/fty005","volume":"76","author":"F Torres-Juarez","year":"2018","unstructured":"Torres-Juarez F et al (2018) RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection. Pathogens Disease 76:fty005","journal-title":"Pathogens Disease"},{"key":"4393_CR110","doi-asserted-by":"publisher","first-page":"e00777","DOI":"10.1128\/spectrum.00777-23","volume":"11","author":"H Tour\u00e9","year":"2023","unstructured":"Tour\u00e9 H, Durand N, Gu\u00e9nal I, Herrmann J-L, Girard-Misguich F, Szuplewski S (2023) Mycobacterium abscessus opsonization allows an escape from the defensin bactericidal action in Drosophila. Microbiol Spectr 11:e00777\u2013e00723","journal-title":"Microbiol Spectr"},{"key":"4393_CR111","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1128\/AAC.00749-08","volume":"53","author":"J van den Boogaard","year":"2009","unstructured":"van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE (2009) New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 53:849\u2013862","journal-title":"Antimicrob Agents Chemother"},{"key":"4393_CR112","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/10826068.2024.2365357","volume":"55","author":"CA Vasquez-Moscoso","year":"2025","unstructured":"Vasquez-Moscoso CA, Merlano JAR, Olivera G\u00e1lvez A, Volcan Almeida D (2025) Antimicrobial peptides (AMPs) from microalgae as an alternative to conventional antibiotics in aquaculture. Prep Biochem Biotechnol 55:26\u201335. https:\/\/doi.org\/10.1080\/10826068.2024.2365357","journal-title":"Prep Biochem Biotechnol"},{"key":"4393_CR113","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","volume":"15","author":"P Vlieghe","year":"2010","unstructured":"Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discovery Today 15:40\u201356","journal-title":"Drug Discovery Today"},{"key":"4393_CR114","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/antibiotics13030278","volume":"13","author":"C Wang","year":"2024","unstructured":"Wang C et al (2024) ApoE mimetic peptide COG1410 kills Mycobacterium smegmatis via directly interfering clpc\u2019s ATPase activity. Antibiotics 13:278","journal-title":"Antibiotics"},{"key":"4393_CR115","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.tube.2011.10.019","volume":"91","author":"KJ Welsh","year":"2011","unstructured":"Welsh KJ, Hwang S-A, Boyd S, Kruzel ML, Hunter RL, Actor JK (2011) Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberculosis 91:S105\u2013S113","journal-title":"Tuberculosis"},{"key":"4393_CR116","first-page":"15","volume":"62","author":"WHO","year":"2009","unstructured":"WHO (2009) Prevention and control of multi-drug-resistant tuberculosis and extensively drug-resistant tuberculosis. World Health Assembly Resolution 62:15","journal-title":"World Health Assembly Resolution"},{"key":"4393_CR117","unstructured":"WHO (2010) Treatment of tuberculosis: guidelines for national programmes. In: World Health Organisation. Accessed on 7 May 2010"},{"key":"4393_CR118","unstructured":"WHO (2016) Global tuberculosis report 2016. In: The World Health Organization (WHO). Accessed on 10 December 2016"},{"key":"4393_CR119","unstructured":"WHO (2024) Global tuberculosis report 2024. In: The World Health Organization. Accessed on 29 October 2024"},{"key":"4393_CR120","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/cb1001558","volume":"5","author":"WC Wimley","year":"2010","unstructured":"Wimley WC (2010) Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 5:905\u2013917","journal-title":"ACS Chem Biol"},{"key":"4393_CR121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hon.681","volume":"20","author":"K Yuen","year":"2002","unstructured":"Yuen K, Woo P (2002) Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 20:51\u201362","journal-title":"Hematol Oncol"},{"key":"4393_CR122","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.bbamem.2006.03.021","volume":"1758","author":"I Zelezetsky","year":"2006","unstructured":"Zelezetsky I, Tossi A (2006) Alpha-helical antimicrobial peptides\u2014Using a sequence template to guide structure\u2013activity relationship studies. Biochim Et Biophys Acta (BBA)-Biomembranes 1758:1436\u20131449","journal-title":"Biochim Et Biophys Acta (BBA)-Biomembranes"},{"key":"4393_CR123","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1517\/14656566.7.6.653","volume":"7","author":"L Zhang","year":"2006","unstructured":"Zhang L, Falla TJ (2006) Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 7:653\u2013663","journal-title":"Expert Opin Pharmacother"},{"key":"4393_CR124","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1359-6446(05)03626-3","volume":"11","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Post-Martens K, Denkin S (2006) New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today 11:21\u201327","journal-title":"Drug Discovery Today"},{"key":"4393_CR125","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/molecules30071529","volume":"30","author":"H Zhang","year":"2025","unstructured":"Zhang H, Lv J, Ma Z, Ma J, Chen J (2025) Advances in antimicrobial peptides: mechanisms, design innovations, and biomedical potential. Molecules 30:1529","journal-title":"Molecules"},{"key":"4393_CR126","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2147\/IDR.S403232","volume":"Resistance","author":"Y-Y Zhao","year":"2023","unstructured":"Zhao Y-Y et al (2023) ApoE mimetic peptide COG1410 exhibits strong additive interaction with antibiotics against Mycobacterium smegmatis. Infect Drug Resistance:1801\u20131812","journal-title":"Infect Drug"},{"key":"4393_CR127","doi-asserted-by":"crossref","unstructured":"Zhao P et al (2024) Microbial-derived peptides with anti-mycobacterial potential. Eur J Med Chem:116687","DOI":"10.1016\/j.ejmech.2024.116687"},{"key":"4393_CR128","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-3156.2010.02665.x","volume":"16","author":"A Zumla","year":"2011","unstructured":"Zumla A et al (2011) Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Tropical Med Int Health 16:79\u201383","journal-title":"Tropical Med Int Health"},{"key":"4393_CR129","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S1473-3099(14)70828-X","volume":"14","author":"A Zumla","year":"2014","unstructured":"Zumla A et al (2014) Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis 14:1136\u20131149","journal-title":"Lancet Infect Dis"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04393-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:09:50Z","timestamp":1757250590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":129,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4393"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04393-1","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"199"}}